Abstract |
The use of CDK4/6 inhibitors, such as palbociclib, has shown promise in treating breast cancer. Data suggest these drugs reverse cell replication farther along in the cell cycle than previously thought-with expanded clinical benefits. Yet, more research is needed to prove that a CDK4/6 inhibitor plus chemotherapy provides irreversible cell senescence because unstable treated cells could replicate and increase risk of disease recurrence.
|
Authors | |
Journal | Cancer discovery
(Cancer Discov)
Vol. 13
Issue 9
Pg. 1955
(09 06 2023)
ISSN: 2159-8290 [Electronic] United States |
PMID | 37489846
(Publication Type: News)
|
Copyright | ©2023 American Association for Cancer Research. |
Chemical References |
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Protein Kinase Inhibitors
|
Topics |
- Humans
- Female
- Neoplasm Recurrence, Local
- Breast Neoplasms
(drug therapy)
- Cell Line, Tumor
- Cell Cycle
- Cyclin-Dependent Kinase 4
(metabolism)
- Cyclin-Dependent Kinase 6
(metabolism)
- Protein Kinase Inhibitors
(therapeutic use)
|